Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP

被引:2
作者
Ming-Shen Dai
Tsu-Yi Chao
Woei-Yau Kao
Rong-Yaun Shyu
Tan-Mei Liu
机构
[1] National Defense Medical Center,Division of Hematology/Oncology, Department of Medicine, Tri
[2] National Defense Medical Center,Service General Hospital
[3] National Defense Medical Center,Division of Gastroenterology, Department of Medicine, Tri
来源
Annals of Hematology | 2004年 / 83卷
关键词
HBV reactivation; Lamivudine; Lymphoma; Preemptive treatment; Rituximab;
D O I
暂无
中图分类号
学科分类号
摘要
Preemptive lamivudine in lymphoma patients undergoing intensive chemotherapy can effectively prevent chemotherapy-related HBV reactivation. Nevertheless, the safety profile after withdrawal of lamivudine and the impact of rituximab-containing chemotherapy on HBV reactivation has not been defined. To illustrate the necessity of prolonged surveillance after cessation of preemptive lamivudine in lymphoma patients treated with rituximab and chemotherapy, four patients with B-cell NHL carrying HBV received rituximab plus CHOP. Preemptive lamivudine therapy was administered 1 week before chemotherapy until 4 weeks after completion of chemotherapy. Serial serum alanine aminotransferase (ALT), total bilirubin, and HBV-DNA levels were prospectively monitored in three patients. The fourth patient was closely monitored for ALT. The HBV DNA was checked after development of clinical overt hepatitis. The peripheral blood CD20+ B-lymphocyte counts were analyzed periodically in two patients. All of the three patients studied prospectively had virological relapses with surgence of HBV DNA 6–8 months after completion of rituximab-plus-CHOP (R+CHOP) therapy. Two of the three patients had biochemical relapses and one of them developed severe hepatitis. Sequencing for HBV polymerase gene in these patients failed to show evident emergence of lamivudine-resistant mutations. The fourth patient developed a hepatitis flare-up 6 months after completion of chemotherapy. The CD20+ lymphocytes were totally depleted when HBV DNA started to increase. Delayed HBV reactivation can occur in lymphoma patients receiving R+CHOP after withdrawal of preemptive lamivudine. More protracted lamivudine therapy may be an alternative to close monitoring following chemotherapy, and further studies are needed to define optimal duration of lamivudine therapy.
引用
收藏
页码:769 / 774
页数:5
相关论文
共 18 条
  • [1] Lok undefined(1991)undefined Gastroenterology 100 182-undefined
  • [2] Liang undefined(1999)undefined J Clin Oncol 17 394-undefined
  • [3] Cheng undefined(2003)undefined Hepatology 37 1320-undefined
  • [4] Leaw undefined(2004)undefined Ann Hematol 5 270-undefined
  • [5] Coiffier undefined(2002)undefined N Engl J Med 346 235-undefined
  • [6] Kolk undefined(2002)undefined Blood 100 2257-undefined
  • [7] Lau undefined(2003)undefined Gastroenterology 125 1742-undefined
  • [8] Yeo undefined(2003)undefined J Med Virol 70 553-undefined
  • [9] Rossi undefined(2001)undefined Br J Haematol 115 58-undefined
  • [10] Hoonkoop undefined(2000)undefined Hepatology 32 635-undefined